AACR 2023
Apr 14 - 19, 2023 | Orlando, FL
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Presentation
Discovery of ARV-766, an Androgen Receptor Degrading PROTAC® for the Treatment of Men with Metastatic Castration Resistant Prostate CancerLB Snyder et al.
Poster
Mechanisms of Acquired Resistance to ARV-471, a Novel PROTAC® Estrogen Receptor DegraderJ Teh et al.
Poster
Enhanced Efficacy of ARV-471, a Novel PROTAC® Estrogen Receptor Degrader, in Combination with Targeted Agents in Estrogen Receptor-Positive (ER+) Breast Cancer ModelsJ Teh et al.